M&T Bank Corp Buys 59,311 Shares of Kenvue Inc. $KVUE

Key Points

• M&T Bank raised its stake in Kenvue by 80.2%, buying 59,311 shares to hold 133,296 shares valued at about $2.30 million; institutional investors own roughly 97.6% of the stock.
• Kenvue topped quarterly expectations with EPS of $0.32 versus $0.27 consensus and revenue of $3.91 billion (vs. $3.84 billion), a 4.5% year‑over‑year increase.
• Kenvue declared a quarterly dividend of $0.2075 ($0.83 annualized) for a 4.7% yield, although the payout ratio is elevated at about 107.8%.

M&T Bank Corp lifted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 80.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 133,296 shares of the company's stock after acquiring an additional 59,311 shares during the quarter. M&T Bank Corp's holdings in Kenvue were worth $2,299,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. D.A. Davidson & CO. grew its stake in shares of Kenvue by 154.8% during the 4th quarter. D.A. Davidson & CO. now owns 39,374 shares of the company's stock valued at $679,000 after acquiring an additional 23,922 shares during the period. Camelot Portfolios LLC bought a new position in shares of Kenvue during the 4th quarter valued at approximately $1,575,000. Kestra Private Wealth Services LLC grew its stake in shares of Kenvue by 1.6% during the 4th quarter. Kestra Private Wealth Services LLC now owns 52,517 shares of the company's stock valued at $906,000 after acquiring an additional 814 shares during the period. Physician Wealth Advisors Inc. grew its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock valued at $26,000 after acquiring an additional 618 shares during the period. Finally, Facet Wealth Inc. bought a new position in shares of Kenvue during the 4th quarter valued at approximately $449,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.3%

KVUE stock opened at $17.74 on Friday. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $25.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. The company has a market capitalization of $34.06 billion, a price-to-earnings ratio of 23.04, a PEG ratio of 4.01 and a beta of 0.55. The business has a 50 day simple moving average of $17.65 and a two-hundred day simple moving average of $17.24.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the prior year, the company posted $0.24 EPS. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. Research analysts anticipate that Kenvue Inc. will post 1.1 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be given a dividend of $0.2075 per share. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date is Wednesday, May 13th. Kenvue's dividend payout ratio is currently 107.79%.

Analyst Ratings Changes

KVUE has been the subject of a number of recent research reports. UBS Group cut their price objective on Kenvue from $19.00 to $18.00 and set a "neutral" rating for the company in a research note on Tuesday, April 7th. Weiss Ratings restated a "hold (c-)" rating on shares of Kenvue in a research note on Wednesday, April 8th. Argus upgraded Kenvue to a "hold" rating in a research note on Friday, March 6th. Jefferies Financial Group downgraded Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Finally, Barclays dropped their price target on Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a research note on Tuesday, April 14th. Three analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.